Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC12A2 | P55011 | 1/20 | 0.56 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283634 | 1.00 | SLC12A2 (0.56) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL2306082 | 1.00 | SLC12A2 (0.56) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL284269 | 0.96 | SLC12A2 (0.52) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL1691225 | 0.96 | SLC12A2 (0.52) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL1691084 | 0.96 | SLC12A2 (0.52) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL19285120 | 0.92 | SLC12A2 (0.47) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL283511 | 0.92 | SLC12A2 (0.47) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL19285370 | 0.92 | SLC12A2 (0.47) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL2929267 | 0.86 | SLC12A2 (0.54) | SLC12A2SLC12A5GAAPOLBALOX12 | |
| SCHEMBL30970528 | 0.86 | SLC12A2 (0.54) | SLC12A2SLC12A5GAAPOLBALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-11 | — | — | US | disclosed |
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2024-05-02 | — | — | US | disclosed |
| US-20240043384-A1 | INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-02-08 | — | — | US | disclosed |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| EP-4223751-A1 | BENZAMIDE COMPOUND AND USE THEREOF | Humanwell Healthcare (Group) Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20230227445-A1 | BENZAMIDE COMPOUND AND USE THEREOF | HUMANWELL HEALTHCARE (GROUP) CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| CN-1087303-C | Catalyst compositions and process for preparing polyolefins | BP CHEM INT LTD (GB) | 2002-07-10 | — | — | CN | disclosed |
| US-6136977-A | Processes for producing phenoxy propionic acid derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| EP-0608054-B1 | Catalyst compositions and process for preparing polyolefins | BP CHEM INT LTD (GB) | 1999-07-07 | — | — | EP | disclosed |
| EP-0912528-A1 | PROCESSES FOR PRODUCING PHENOXY PROPIONIC ACID DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-05-06 | — | — | EP | disclosed |
| US-5814574-A | ZIRCONIUM METALLOCENE POLYMERIZATION CATALYSTS; NARROW MOLECULAR WEIGHT DISTRIBUTION | BP CHEMICALS LIMITED (GB) | 1998-09-29 | — | — | US | disclosed |
| US-5767209-A | A METALLOCENE COMPLEX OF A GROUP 4 METAL AND A CYCLOPENTADIENYL NUCLEUS ON AN INORGANIC SUPPORT WITHOUT USING COCATALYSTS, E.G. ALUMOXANES, AS THE MEANS OF SUPPORT | BP CHEMICALS LIMITED (GB) | 1998-06-16 | — | — | US | disclosed |
| WO-1997046538-A1 | PROCESSES FOR PRODUCING PHENOXY PROPIONIC ACID DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1997-12-11 | — | — | WO | disclosed |
| CN-1092081-A | Catalyst composition and preparation of polyolefins method | BP CHEM INT LTD (GB) | 1994-09-14 | — | — | CN | disclosed |
| EP-0608054-A2 | Catalyst compositions and process for preparing polyolefins | BP Chemicals Limited (GB) | 1994-07-27 | — | — | EP | disclosed |
| US-4087532-A | Analgesically useful 2-tetrahydrofurfuryl-5-lower alkyl-2-oxy-6,7-benzomorphans and salts thereof | BOEHRINGER INGELHEIM GMBH (DT) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | ADCK1, DCK, TNKS2 | SLC12A2 3849/4885SLC12A5 3871/4885GAA 1621/4885 |
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | SLC12A2 1856/4885SLC12A5 2201/4885GAA 90/4885 |
| US-20230227445-A1 | BENZAMIDE COMPOUND AND USE THEREOF | P2RX3, P2RX4, P2RX7 | SLC12A2 369/4885SLC12A5 270/4885GAA 1794/4885 |
| US-20240043384-A1 | INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE | CREBBP, JUN, SP1 | SLC12A2 1682/4885SLC12A5 1639/4885GAA 1526/4885 |
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | SLC12A2 2023/4885SLC12A5 2042/4885GAA 4482/4885 |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | SLC12A2 2023/4885SLC12A5 2042/4885GAA 4482/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | SLC12A2 4067/4885SLC12A5 3817/4885GAA 2465/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | SLC12A2 4067/4885SLC12A5 3817/4885GAA 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.